RT Journal Article
SR Electronic
T1 Cell-mediated and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.04.22268750
DO 10.1101/2022.01.04.22268750
A1 Yang, Lu M.
A1 Costales, Cristina
A1 Ramanathan, Muthukumar
A1 Bulterys, Philip L.
A1 Murugesan, Kanagavel
A1 Schroers-Martin, Joseph
A1 Alizadeh, Ash A.
A1 Boyd, Scott D.
A1 Brown, Janice M.
A1 Nadeau, Kari C.
A1 Nadimpalli, Sruti S.
A1 Wang, Aileen X.
A1 Busque, Stephan
A1 Pinsky, Benjamin A.
A1 Banaei, Niaz
YR 2022
UL http://medrxiv.org/content/early/2022/01/05/2022.01.04.22268750.abstract
AB Importance Data on the humoral and cellular immune response to primary and booster SARS-CoV-2 vaccination in immunosuppressed patients is limited.Objective To determine humoral and cellular response to primary and booster vaccination in immunosuppressed patients and identify variables associated with poor response.Design Retrospective observational cohort study.Setting Large healthcare system in Northern California.Participants This study included patients fully vaccinated against SARS-CoV-2 (mRNA-1273, BNT162b2, or Ad26.COV2.S) who underwent clinical testing for anti-SARS-SoV-2 S1 IgG ELISA (anti-S1 IgG) and SARS-CoV-2 interferon gamma release assay (IGRA) from January 1, 2021 through November 15, 2021. A cohort of 18 immunocompetent volunteer healthcare workers were included as reference. No participants had a prior diagnosis of SARS-CoV-2 infection.Exposure(s) Immunosuppressive diseases and therapies.Main Outcome(s) and Measure(s) Humoral and cellular SARS-CoV-2 vaccine response as measured by anti-S1 IgG and SARS-CoV-2 IGRA, respectively, after primary and booster vaccination.Results 496 patients (54% female; median age 50 years) were included in this study. Among immunosuppressed patients after primary vaccination, 62% (261/419) had positive anti-S1 IgG and 71% (277/389) had positive IGRA. After booster, 69% (81/118) had positive anti-S1 IgG and 73% (91/124) had positive IGRA. Immunosuppressive factors associated with low rates of humoral response after primary vaccination included anti-CD20 monoclonal antibodies (P<.001), sphingosine 1-phsophate (S1P) receptor modulators (P<.001), mycophenolate (P=.002), and B cell lymphoma (P=.004); those associated with low rates of cellular response included S1P receptor modulators (P<.001) and mycophenolate (P<.001). Of patients who responded poorly to primary vaccination, 16% (4/25) with hematologic malignancy or primary immunodeficiency developed a significantly increased humoral response after the booster dose, while 52% (14/27) with solid malignancy, solid organ transplantation, or autoimmune disease developed an increased response (P=.009). Only 5% (2/42) of immunosuppressed patients developed a significantly increased cellular response following the booster dose.Conclusions and Relevance Cellular vaccine response rates were higher than humoral response rates in immunosuppressed individuals after primary vaccination, particularly among those undergoing B cell targeting therapies. However, humoral response can be increased with booster vaccination, even in patients on B cell targeting therapies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Stanford University Institutional Review Board (IRB-60171 and IRB-57519). Informed consent was obtained from volunteer healthcare workers before blood collection.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified raw data used in the study is available upon request.CLLchronic lymphocytic leukemiaCVIDcommon variable immunodeficiencyHCWhealthcare workerHSCThematopoietic stem cell transplantIgimmunoglobulinsIgG assayanti-S1 IgG enzyme-linked immunosorbent assay (Euroimmun)IGRAinterferon-γ (INF-γ) release assay (Stanford)ISMTimmune-suppressive/modulatory therapyISPimmunosuppressed patientmAbsmonoclonal antibodiesMBLmonoclonal B cell lymphocytosisMDSmyelodysplastic syndromeMGUSmonoclonal gammopathy of unknown significanceMPNmyeloproliferative neoplasmMSmultiple sclerosisNISPnon-immunosuppressed patientNMOneuromyelitis opticaS1Psphingosine 1-phosphateSLEsystemic lupus erythematosusSLLsmall lymphocytic lymphoma